Pre-made Andecaliximab benchmark antibody ( Whole mAb, anti-MMP9/MMP-9 therapeutic antibody, Anti-CLG4B/GELB/MANDP2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-024

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-024 Category Tag

Product Details

Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

Products Name (INN Index)

Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody

INN Name

Andecaliximab

Target

MMP9

Format

Whole mAb

Derivation

Chimeric (Mouse/Human)

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Discontinued

100% SI Structure

5th9:HL:IM:JN

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2016

Companies

Gilead Sciences

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Chronic obstructive pulmonary disease,Crohn's disease,Cystic fibrosis,Rheumatoid arthritis,Ulcerative colitis,Gastric cancer,Solid tumours,Glioblastoma

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

MMP9/MMP-9

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide